Cm-101 a novel CCL24 blocking monoclonal antibody demonstrates safety, target engagement and long half-life in a phase 1 randomized, controlled single ascending dose trial using iv and sc formulations in healthy subjects

Authors
Category Primary study
ConferenceHepatology
Year 2020
This article has no abstract
Epistemonikos ID: b231a684c1f351e881681559690ce3d74f2d06bd
First added on: Apr 30, 2026